MacroGenics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

MacroGenics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.5%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.5%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von MGNX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von MGNX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

MacroGenics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von MGNX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (MGNX)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (MGNX) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von MGNX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von MGNX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von MGNX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da MGNX keine Ausschüttungen gemeldet hat.

MacroGenics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Consensus revenue estimates increase by 17%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Price target decreased by 9.4% to US$7.25

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Macrogenics Provides Vobramitamab Duocarmazine Update

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Price target decreased by 25% to US$8.11

MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Block & Leviton Files Lawsuit Against MacroGenics, Inc

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

New major risk - Financial position

Consensus EPS estimates fall by 18%

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

New minor risk - Share price stability

Consensus revenue estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target increased by 9.9% to US$16.00

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

President exercised options and sold US$250k worth of stock

MacroGenics: Trying To Build A Better Everything

Price target increased by 8.1% to US$14.78

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Price target increased by 12% to US$14.33

Insider notifies of intention to sell stock

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment improves as stock rises 18%

Consensus revenue estimates decrease by 25%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Investor sentiment deteriorates as stock falls 15%

Insider recently bought US$74k worth of stock

Investor sentiment deteriorates as stock falls 16%

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates fall by 13%

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Price target increased by 11% to US$11.75

Consensus revenue estimates increase by 42%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus EPS estimates fall by 10%

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Price target decreased to US$10.40

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Price target increased to US$12.33

Consensus revenue estimates increase by 11%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus forecasts updated

MacroGenics: No Near-Term Catalysts

Price target decreased to US$10.72

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Consensus revenue estimates increase by 11%